| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/(SICI)1098-2264(199908)25:4<339::AID-GCC5>3.0.CO;2-H |
| P698 | PubMed publication ID | 10398427 |
| P50 | author | Richard F. Kefford | Q46460242 |
| P2093 | author name string | Schmid H | |
| Mann GJ | |||
| Holland EA | |||
| P433 | issue | 4 | |
| P304 | page(s) | 339-348 | |
| P577 | publication date | 1999-08-01 | |
| P1433 | published in | Genes, Chromosomes and Cancer | Q5532697 |
| P1476 | title | CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas | |
| P478 | volume | 25 |
| Q36808635 | A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). |
| Q58485779 | Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma |
| Q34212766 | Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study |
| Q28215807 | Association of p14ARF with the p120E4F transcriptional repressor enhances cell cycle inhibition |
| Q57314787 | Better the Devil You Know? High-Risk Individuals’ Anticipated Psychological Responses to Genetic Testing for Melanoma Susceptibility |
| Q36643400 | CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation |
| Q79079264 | CDKN2A as a uveal and cutaneous melanoma susceptibility gene |
| Q36376583 | Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. |
| Q28078465 | Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility |
| Q37004819 | Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents |
| Q90455618 | Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma |
| Q37137000 | Genetic Determinants of Cutaneous Melanoma Predisposition |
| Q37341178 | Genome-wide association study identifies three loci associated with melanoma risk |
| Q36694476 | Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma |
| Q37118264 | Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas |
| Q52858162 | Intronic sequence variants of the CDKN2A gene in melanoma pedigrees. |
| Q42521143 | Multiple primary melanoma revisited |
| Q24801244 | Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B |
| Q34107950 | New developments in melanoma genetics |
| Q61917486 | No Evidence for Linkage with Melanoma in Italian Melanoma-Prone Families |
| Q39722414 | Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. |
| Q35840024 | Selection criteria for genetic assessment of patients with familial melanoma |
| Q34344031 | Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma |
| Q33693906 | State of melanoma: an historic overview of a field in transition |
| Q79435498 | The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry |
| Q35126570 | The Sydney Melanoma Unit--a multidisciplinary melanoma treatment center |
| Q34964393 | The dilemma of the dysplastic nevus |
| Q36971412 | p16INK4a-induced senescence is disabled by melanoma-associated mutations |
Search more.